Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : SVB Leerink Adjusts Amgen's Price Target to $234 from $238, Keeps Market Perform Rating

08/04/2021 | 10:27am EST


ę MT Newswires 2021
All news about AMGEN INC.
05:22pAMGEN : Bradway Hails Amgen's Progress Against 'Undruggable' Disease Targets at Two Health..
PU
04:06pAmgen Raises Fiscal Q1 Dividend 10% to $1.94 a Share, Payable March 8 to Shareholders o..
MT
04:01pAmgen Announces 10% Increase In 2022 First Quarter Dividend
PR
05:53aBiotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/01Amgen Arthritis Drug Shows Promise as Psoriasis Medication During Phase III Testing
MT
12/01Amgen Announces Positive Top-Line Results From Otezla« (apremilast) Phase 3 DISCREET St..
PR
12/01Amgen Inc. Announces Positive Top-Line Results From Otezla? Phase 3 DISCREET Study In M..
CI
12/01Johnson & Johnson's Janssen Lands FDA Nod for Multiple Myeloma Treatment
MT
12/01Amgen Gets FDA Nod for New Kyprolis Combo Regimen for Multiple Myeloma
MT
12/01Amgen Says FDA Approves Kyprolis Combination to Treat Multiple Myeloma
DJ
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 018 M - -
Net income 2021 5 551 M - -
Net Debt 2021 22 411 M - -
P/E ratio 2021 20,5x
Yield 2021 3,44%
Capitalization 114 B 114 B -
EV / Sales 2021 5,24x
EV / Sales 2022 4,92x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 202,44 $
Average target price 238,86 $
Spread / Average Target 18,0%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-12.50%113 312
JOHNSON & JOHNSON-0.18%413 555
ROCHE HOLDING AG17.62%341 509
PFIZER, INC.44.09%297 706
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726